Aconjugate vaccineis created by attaching covalently, a poorantigen (most commonly, a polysaccharide)to a strongantigen,thereby eliciting a stronger immunological response to the poor antigen. However, peptide/protein and protein/protein conjugates have also been developed. It is a vaccine containing bacterial capsular polysaccharide, joined to a protein to enhance immunogenicity and protect against invasive diseases.

Chapter 1: Executive summary

Chapter 2: Market overview

Chapter 3: Major segment overview global by disease indication

Chapter 4: Major segment overview global by end user

Chapter 5: North America by disease indication

Chapter 6: North America by end user

Chapter 7: Europe by disease indication

Chapter 8: Europe by end user

Chapter 9: Asia-Pacific by disease indication

Chapter 10: Asia-Pacific by end user

Chapter 11: Latin America by disease indication

Chapter 12: Latin America by end user

Chapter 13: The Middle East &Africa by disease indication

Chapter 14: The Middle East &Africa by end user

Chapter 15: Competitive landscape